Reference List
(1) [3d National Congress on Transfusion Safety and Hemovigilance. Lille, France, 16-7 September 1999.
Proceedings and abstracts]. Transfus Clin Biol 2000 Feb;7(1):5-49.
(2) Haemovigilance. Vox Sang 2006 Apr;90(3):207-41.
(3) [Proceedings and abstracts of the 8th National Congress on Transfusion Safety and Hemovigilance, 19-21
November 2008, Perpignan, France]. Transfus Clin Biol 2008 Nov;15(5):193-375.
(4) Allain JP. Transfusion risks of yesterday and of today. Transfus Clin Biol 2003 Feb;10(1):1-5.
(5) Allegra A, Penna G, Alonci A, Granata A, D'Angelo A, Musolino C. Exacerbation of chronic idiopathic
thrombocytopenic purpura following reactivation of an occult hepatitis B. Med Oncol 2009 Sep 23.
(6) Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, et al. Hemovigilance network in France:
organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002
Oct;42(10):1356-64.
(7) Andreu G, Vasse J, Sandid I, Tardivel R, Semana G. Use of random versus apheresis platelet concentrates.
Transfus Clin Biol 2007 Dec;14(6):514-21.
(8) Andreu G, Vasse J, Herve F, Tardivel R, Semana G. [Introduction of platelet additive solutions in transfusion
practice. Advantages, disadvantages and benefit for patients]. Transfus Clin Biol 2007 May;14(1):100-6.
(9) Arewa OP, Akinola NO, Salawu L. Blood transfusion reactions; evaluation of 462 transfusions at a tertiary
hospital in Nigeria. Afr J Med Med Sci 2009 Jun;38(2):143-8.
(10) Arewa OP. Improving supply of safe blood and reducing cost of transfusion service through haemovigilance.
Niger Postgrad Med J 2009 Dec;16(4):236-8.
(11) Arslan O. Haemovigilance in developing countries. Hematology 2005;10 Suppl 1:79-81.
(12) AuBuchon JP, Whitaker BI. America finds hemovigilance! Transfusion 2007 Oct;47(10):1937-42.
(13) Aullen JP, Delbosc A, Ferrer Le CF, Riviere P, Schlanger S. [Adverse unidentified transfusion reactions in
five French regions: analysis, results, propositions]. Transfus Clin Biol 2010 Feb;17(1):20-7.
(14) Ayob Y. Hemovigilance in developing countries. Biologicals 2010 Jan;38(1):91-6.
(15) Balen S, Caser L, Ivankovic E, Samardzija M, Ivankovic Z, Vcev A. Evaluation of fresh frozen plasma usage
at the University Hospital Center Rijeka. Coll Antropol 2009 Dec;33(4):1375-81.
(16) Baudelot J, Djoudi R. [From the transfusion informationcard to the tracing of blood products]. Cah
Anesthesiol 1994;42(3):379-83.
(17) Baudoux E, Margraff U, Coenen A, Jacobs X, Strivay M, Lungu C, et al. Hemovigilance: clinical tolerance of
solvent-detergent treated plasma. Vox Sang 1998;74 Suppl 1:237-9.
(18) Baudoux E, Blaffart F, Bouffioux C, Caprasse M, Courtois F, Cremasco MR, et al. [The Hemovigilance
Commission of the University Hospital Center]. Rev Med Liege 2000 Sep;55(9):878-80.
(19) Beauplet A. [The transfusion chain: from donor to recipient]. Rev Prat 2001 Jun 30;51(12):1294-8.
(20) Beckers EA, Dinkelaar RB, te Boekhorst PA, van Ingen HE, van Rhenen DJ. [Reports of transfusion
incidents: experiences from the first year of hemovigilance in the region of the former ZWN (South West
Netherlands) blood bank in Rotterdam]. Ned Tijdschr Geneeskd 2003 Aug 2;147(31):1508-12.
(21) Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion-transmitted infections. J Transl Med
2007;5:25.
(22) Botte C, Janot C. Epidemiology of HCV infection in the general population and in blood transfusion. Nephrol
Dial Transplant 1996;11 Suppl 4:19-21.
(23) Burrows JM, Callum JL, Belo S, Etchells E, Leeksma A. Variable pre-transfusion patient identification
practices exist in the perioperative setting. Can J Anaesth 2009 Dec;56(12):901-7.
(24) Buser A, Sigle J, Halter J. [Blood transfusions in the treatment of chronic anemia.]. Ther Umsch 2010
May;67(5):265-9.
(25) Cahill MR, Joyce S, O'Brien N, Casey M. Haemovigilance is associated with decreased use and improved
appropriateness of blood transfusion. Vox Sang 2003 Aug;85(2):121-2.
(26) Canivet N, Hollander K, Mousnier JP, Quaranta JF. [Materials surveillance, a surveillance performed on the
use of medical devices]. Transfus Clin Biol 2000 Feb;7(1):96-100.
(27) Carre J. [Computer-assisted management of depots for blood products in health establishments]. Transfus
Clin Biol 2008 Nov;15(5):197-200.
(28) Cazenave JP. [Pathogen inactivation in labile blood products: transfusion safety and economic impact]. Bull
Acad Natl Med 2006 Jan;190(1):169-85.
(29) Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, et al. An active hemovigilance program
characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and
UVA photochemical treatment. Transfusion 2010 Jan 22.
(30) Cesaire R, Kerob-Bauchet B, Bourdonne O, Maier H, Amar KO, Halbout P, et al. Evaluation of HTLV-I
removal by filtration of blood cell components in a routine setting. Transfusion 2004 Jan;44(1):42-8.
(31) Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, et al. Ten years of hemovigilance reports of
transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor
plasma. Transfusion 2009 Mar;49(3):440-52.
(32) Courbil R, Quaranta JF. [Blood transfusion and blood-derived products: indications, complications.
Haemovigilance]. Rev Prat 2004 Dec 15;54(19):2177-86.
(33) Danic B, Gouezec H, Bigant E, Thomas T. [Incidents of blood donation]. Transfus Clin Biol 2005
Jun;12(2):153-9.
(34) Daurat G, Fressy P, Duedari N, Le BG, Taverne D, Ounnoughene N, et al. [Evaluation of pre- and posttransfusion serological screening in France in 2001]. Transfus Clin Biol 2004 Jul;11(3):153-60.
(35) Daurat G, Duedari N, Schved JF. [The decrease of preoperative autologous transfusion in France has not been
linked to an increase of homologous red cell concentrates]. Ann Fr Anesth Reanim 2008 Feb;27(2):141-7.
(36) David B. [State and perspectives of the French haemovigilance system. Presentation of the data collected over
9 years]. Transfus Clin Biol 2003 Jun;10(3):131-9.
(37) De SG, Bagatella P, Tison T, Quaino V, Carraro P, Tenderini ML, et al. Virus-inactivated plasma Plasmasafe: a one-year experience. Blood Transfus 2007 Jul;5(3):134-42.
(38) Debeir J, Noel L, Aullen J, Frette C, Sari F, Mai MP, et al. The French haemovigilance system. Vox Sang
1999;77(2):77-81.
(39) Deimann LG. [Reports of transfusion incidents: experiences from the first year of hemovigilance in the region
of the former ZWN (South West Netherlands) blood bank in Rotterdam]. Ned Tijdschr Geneeskd 2004 Jan
3;148(1):50.
(40) Desachy A, Vuagnat A, Masse S, Baudin O, Vacher P, Calvat S, et al. [Prospective assessment of information
programme for blood transfusion in critical care patients]. Ann Fr Anesth Reanim 2003 Oct;22(8):704-10.
(41) Dodd R, Kurt RW, Ashford P, Dax EM, Vyas G. Transfusion medicine and safety. Biologicals 2009
Apr;37(2):62-70.
(42) Doly A, Fressy P, Garraud O. [Relevance of the hemovigilance regional database for the shared medical file
identity server]. Transfus Clin Biol 2008 Nov;15(5):269-73.
(43) Durand F, Danic B, Tardivel R, Semana G, Gouezec H, Martinot M, et al. [Discovery of a chronic HVC
infection without seroconversion in a blood donor in France during 28 months]. Transfus Clin Biol 2000
Jun;7(3):242-50.
(44) Dzik WH. Emily Cooley Lecture 2002: transfusion safety in the hospital. Transfusion 2003 Sep;43(9):1190-9.
(45) Dzik WH. New technology for transfusion safety. Br J Haematol 2007 Jan;136(2):181-90.
(46) Eder A, Goldman M, Rossmann S, Waxman D, Bianco C. Selection criteria to protect the blood donor in
North America and Europe: past (dogma), present (evidence), and future (hemovigilance). Transfus Med Rev
2009 Jul;23(3):205-20.
(47) Eder AF, Dy BA, Kennedy JM, Notari Iv EP, Strupp A, Wissel ME, et al. The American Red Cross donor
hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008
Sep;48(9):1809-19.
(48) Eder AF, Dy BA, Barton J, Kennedy JM, Benjamin RJ. The American Red Cross Hemovigilance Program:
advancing the safety of blood donation and transfusion. Immunohematology 2009;25(4):179-85.
(49) Eder AF, Herron Jr RM, Strupp A, Dy B, White J, Notari EP, et al. Effective reduction of transfusion-related
acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008).
Transfusion 2010 Apr 30.
(50) Edgren G, Hjalgrim H, Tran TN, Rostgaard K, Shanwell A, Titlestad K, et al. A population-based binational
register for monitoring long-term outcome and possible disease concordance among blood donors and
recipients. Vox Sang 2006 Nov;91(4):316-23.
(51) El KH, Vandenvelde C. [Transfusion-related acute lung injury (TRALI): emerging or main transfusion
hazard?]. Rev Med Brux 2005;26 Spec no:Sp31-Sp35.
(52) Engelfriet CP, Reesink HW, Brand B, Levy G, Williamson LM, Menitove JE, et al. Haemovigilance systems.
Vox Sang 1999;77(2):110-20.
(53) Epstein JS. Alternative strategies in assuring blood safety: An overview. Biologicals 2010 Jan;38(1):31-5.
(54) Espinosa A, Steinsvag CT, Flesland O. Hemovigilance in Norway. Transfus Apher Sci 2005 Feb;32(1):17-9.
(55) Faber JC. [Blood surveillance in Europe]. Transfus Clin Biol 2000 Feb;7(1):5-8.
(56) Faber JC. Haemovigilance in Europe: the European Haemovigilance Network. Transfus Clin Biol 2001
Jun;8(3):285-90.
(57) Faber JC. Haemovigilance around the world. Vox Sang 2002 Aug;83 Suppl 1:71-6.
(58) Faber JC. Worldwide overview of existing haemovigilance systems. Transfus Apher Sci 2004 Oct;31(2):99110.
(59) Faber JC. Haemovigilance procedure in transfusion medicine. Hematol J 2004;5 Suppl 3:S74-S82.
(60) Faber JC. Work of the European Haemovigilance Network (EHN). Transfus Clin Biol 2004 Feb;11(1):2-10.
(61) Faber JC. [Review of the main haemovigilance systems in the world]. Transfus Clin Biol 2009 May;16(2):8692.
(62) Fialon P, Quaranta JF, Lemonnier MP, Bricard H, Nublat M, Laxenaire MC, et al. [Assessment of the
implementation of the hemovigilance and transfusion safety system in French hospitals and blood transfusion
centers]. Transfus Clin Biol 1998 Jun;5(3):193-202.
(63) Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med
2007 Jun;33 Suppl 1:S17-S21.
(64) Frere MC, Rapaille A, Bouillenne C, Gerard C, Sondag D, Verhees A. [Analysis of 516 reports of reactions
after the transfusion of labile blood products]. Transfus Clin Biol 2001 Aug;8(4):333-42.
(65) Fressy P, Daurat G, Duedari N, Le BG, Taverne D, Ounnoughene N, et al. [Evaluation of the organization of
pre and post transfusion screening of viral infection markers in blood recipients in France in 2001]. Transfus
Clin Biol 2005 Oct;12(4):295-300.
(66) Frietsch T, Weiler-Lorentz A, Schipplick M, Kretschmer V. [The German interdisciplinary taskforce for
clinical hemotherapy IAKH and its national critical incident reporting system specifically for blood
transfusion]. Anasthesiol Intensivmed Notfallmed Schmerzther 2009 Sep;44(9):626-8.
(67) Fung YL, Goodison KA, Wong JK, Minchinton RM. Investigating transfusion-related acute lung injury
(TRALI). Intern Med J 2003 Jul;33(7):286-90.
(68) Funk MB, Gunay S, Lohmann A, Henseler O, Keller-Stanislawski B. [Evaluation of measures aimed to
reduce serious adverse transfusion reactions (hemovigilance data from 1997 to 2008)].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010 Apr;53(4):347-56.
(69) Galuszkova D, Galuszka J. Haemotherapy analysis: the Teaching Hospital Olomouc in 2006. Biomed Pap
Med Fac Univ Palacky Olomouc Czech Repub 2007 Dec;151(2):349-51.
(70) Garozzo G, Crocco I, Giussani B, Martinucci A, Monacelli S, Randi V. Adverse reactions to blood donations:
the READ project. Blood Transfus 2010 Jan;8(1):49-62.
(71) Giampaolo A, Piccinini V, Catalano L, Abbonizio F, Hassan HJ. The first data from the haemovigilance
system in Italy. Blood Transfus 2007 Apr;5(2):66-74.
(72) Glynn A, McCarthy T, McCarroll M, Murray P. A prospective audit of blood usage post primary total knee
arthroplasty. Acta Orthop Belg 2006 Jan;72(1):24-8.
(73) Heier HE. [Hemovigilance--a new name or an old, unfulfilled need]. Tidsskr Nor Laegeforen 2000 Aug
10;120(18):2185.
(74) Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004
Sep;11(5):346-50.
(75) Hervig T, Flesland O, Svenningsen V, Bosnes V. Guidelines for transfusion in Norway. Transfus Apher Sci
2004 Dec;31(3):181-4.
(76) Humpe A, Legler TJ, Nubling CM, Riggert J, Unger G, Wolf C, et al. Hepatitis C virus transmission through
quarantine fresh-frozen plasma. Thromb Haemost 2000 Nov;84(5):784-8.
(77) Ingrand P, Salmi LR, Benz-Lemoine E, Dupuis M. [Evaluation of the actual traceability of labile blood
products using medical records]. Transfus Clin Biol 1998 Dec;5(6):397-407.
(78) Janvier G, Fialon P. [Synthesis of the debates of the 2d National Congress of Transfusion Safety and
Hemovigilance]. Transfus Clin Biol 1998 Jun;5(3):189-92.
(79) Jorgensen JR, Taaning EB. [Registration of complications after transfusion--"hemovigilance"]. Ugeskr Laeger
1999 Nov 29;161(48):6610-2.
(80) Jullien AM. [Transfusion and hepatitis C]. Pathol Biol (Paris) 1995 Oct;43(8):725-34.
(81) Keller-Stanislawski B, Lohmann A, Gunay S, Heiden M, Funk MB. The German Haemovigilance System-reports of serious adverse transfusion reactions between 1997 and 2007. Transfus Med 2009 Dec;19(6):340-9.
(82) Keller-Stanislawski B, Reil A, Gunay S, Funk MB. Frequency and severity of transfusion-related acute lung
injury--German haemovigilance data (2006-2007). Vox Sang 2010 Jan;98(1):70-7.
(83) Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada.
Transfus Med Rev 2003 Apr;17(2):120-62.
(84) Lagneaux MC, Savy-Balichard C, Morel MC, Berthoux JM. [Nurses and risk management. Transfusion
safety and prevention of risks]. Soins 2000 Jan;(642):41-3.
(85) Laperche S. [Practical repercussions of 3 years of experience of national hemovigilance on the subject of viral
complications]. Transfus Clin Biol 1998 Jun;5(3):211-8.
(86) Lapierre V, Auperin A, Robinet E, Ferrand C, Oubouzar N, Tramalloni D, et al. Immune modulation and
microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer
patients: results of a randomized study. Transfusion 2007 Sep;47(9):1691-9.
(87) Lartigue B, Coffin S, Pottier M. [Contribution of electronic data interchange to haemovigilance in a hospital-experience in the University Hospital of Reims]. Transfus Clin Biol 2009 Nov;16(5-6):474-81.
(88) Lassale B, Legrand D, Chiaroni J. [Reorganization of blood watch and transfusion safety activities in the
Marseille public hospital system in partnership between the French blood institute Alps Mediterranean
division (EFS AM)]. Transfus Clin Biol 2010 Feb;17(1):34-7.
(89) Lawson-Ayayi S, Salmi LR. Epidemiology of blood collection in France. Eur J Epidemiol 1999
Mar;15(3):285-92.
(90) Le DL, Lepiouf L, Leostic C, Barra JA, Le NC. [A quality program in haemovigilance: evaluation of the
blood transfusion chain]. Transfus Clin Biol 2004 Jul;11(3):138-45.
(91) Le NC, Lepiouf L. [Professional-practice evaluation of the medical and nursing dysfunctions observed during
the transfusion chain at the University Hospital of Brest]. Transfus Clin Biol 2007 Nov;14(5):457-63.
(92) Lefrere JJ, Coudurier N. [Biobanks and blood transfusion in France: a tool for public health]. Transfus Clin
Biol 2009 May;16(2):148-51.
(93) Lobel B, Blitz M, Anidjar M, Sachot JL, Abbou C, Mignard JP, et al. [Endoscopes in urology: disinfection,
sterilization, labeling and tracking. Circulars and decrees. Modes of application and commentary. The
Committee of Infectious Diseases of the French Association of Urology. Congressional forum UFA--Paris,
November 1996. DGS Circular 20 October 1997]. Prog Urol 1998 Feb;8(1):106-12.
(94) Lozach P, Vicariot M, Le NC, Pomey MP, Lejeune B, Ferec C, et al. [Evaluation of the immediate
transfusion reaction incident reporting system at the Brest University Hospital Center]. Transfus Clin Biol
2001 Aug;8(4):343-9.
(95) Luban NL. Transfusion safety: Where are we today? Ann N Y Acad Sci 2005;1054:325-41.
(96) Lundy D, Laspina S, Kaplan H, Rabin FB, Lawlor E. Seven hundred and fifty-nine (759) chances to learn: a
3-year pilot project to analyse transfusion-related near-miss events in the Republic of Ireland. Vox Sang 2007
Apr;92(3):233-41.
(97) Martiniere K, Mai MP, Cabaud JJ, Schweizer H, Legras JF, Zorzi P. [Transfusion incidents reports of grade
zero: a national and descriptive analysis upon two years of practical survey]. Transfus Clin Biol 2005
Dec;12(6):412-22.
(98) Mathai J. Problem of bacterial contamination in platelet concentrates. Transfus Apher Sci 2009
Oct;41(2):139-44.
(99) Mauricio R, de SG, Seghatchian J. What's happening: an overview of potential adverse reactions associated
with apheresis technology. Transfus Apher Sci 2005 Nov;33(3):351-6.
(100) Mayr WR. Blood transfusion in Europe--The White Book 2005: the patchwork of transfusion medicine in
Europe. Transfus Clin Biol 2005 Nov;12(5):357-8.
(101) McClelland B, Love E, Scott S, Williamson LM. Haemovigilance: concept, Europe and UK initiatives. Vox
Sang 1998;74 Suppl 2:431-9.
(102) McClelland B, Contreras M. Appropriateness and safety of blood transfusion. BMJ 2005 Jan
15;330(7483):104-5.
(103) Menitove JE. Hemovigilance in the United States of America. Vox Sang 1998;74 Suppl 2:447-55.
(104) Michlig C, Vu DH, Wasserfallen JB, Spahn DR, Schneider P, Tissot JD. Three years of haemovigilance in a
general university hospital. Transfus Med 2003 Apr;13(2):63-72.
(105) Migeot V, Aballea P, Duedari N, Besse-Moreau M, Houssay D, Ingrand P. [Regional program to improve the
quality of blood transfusions in hospitals: experience of the Poitou-Charentes region]. Transfus Clin Biol
2001 Feb;8(1):23-9.
(106) Migeot V, Tellier S, Ingrand P. [Diversity of bedside pretransfusion ABO compatibility devices in
metropolitan France]. Transfus Clin Biol 2003 Feb;10(1):26-36.
(107) Milkins C. Performance and practice in UK hospital transfusion laboratories. Transfus Apher Sci 2007
Apr;36(2):129-31.
(108) Moog R. Report about the haemovigilance postgraduate course of the interdisciplinary European society for
haemapheresis and haemotherapy. Transfus Apher Sci 2007 Oct;37(2):177-8.
(109) Morel P, Herve P. Surveillance of blood transfusion safety: contribution of the hemovigilance strategy in
France. Transfus Med Rev 1998 Apr;12(2):109-27.
(110) Morel P, Leconte des Floris MF, Bardiaux L, Pouthier F, Herve P. [Blood transfusion and bacterial risk].
Transfus Clin Biol 2000 Jun;7 Suppl 1:55s-62s.
(111) Morel P, Leconte des Floris MF, Bardiaux L, Pouthier F, Herve P. [Blood transfusion and bacterial risk].
Transfus Clin Biol 2000 Feb;7(1):15-23.
(112) Munksgaard L, Albjerg L, Lillevang ST, Gahrn-Hansen B, Georgsen J. Detection of bacterial contamination
of platelet components: six years' experience with the BacT/ALERT system. Transfusion 2004
Aug;44(8):1166-73.
(113) Munoz M, Garcia-Erce JA, Villar I, Thomas D. Blood conservation strategies in major orthopaedic surgery:
efficacy, safety and European regulations. Vox Sang 2009 Jan;96(1):1-13.
(114) Murphy MF. Surveillance of transfusion errors: putting data to use in the U.K. Dev Biol (Basel)
2005;120:179-87.
(115) Namen-Lopes MS, Martins ML, Drummond PC, Lobato RR, Carneiro-Proietti AB. Lookback study of
HTLV-1 and 2 seropositive donors and their recipients in Belo Horizonte, Brazil. Transfus Med 2009
Aug;19(4):180-8.
(116) Nance ST. How to find, recruit and maintain rare blood donors. Curr Opin Hematol 2009 Nov;16(6):503-8.
(117) Noel L. [Quality assurance of bacterial incidents associated with blood transfusion]. Transfus Clin Biol
1996;3(1):35-42.
(118) Noel L, Debeir J, Cosson A. The French haemovigilance system. Vox Sang 1998;74 Suppl 2:441-5.
(119) Norda R, Tynell E, Akerblom O. Cumulative risks of early fresh frozen plasma, cryoprecipitate and platelet
transfusion in Europe. J Trauma 2006 Jun;60(6 Suppl):S41-S45.
(120) Nubling CM, Heiden M, Chudy M, Kress J, Seitz R, Keller-Stanislawski B, et al. Experience of mandatory
nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough
transmissions. Transfusion 2009 Sep;49(9):1850-8.
(121) Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, et al. An active
haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with
amotosalen photochemical treatment. Vox Sang 2008 May;94(4):315-23.
(122) Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, et al. Universal adoption of pathogen
inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009
Jul;49(7):1412-22.
(123) Pagliaro P, Rebulla P. Transfusion recipient identification. Vox Sang 2006 Aug;91(2):97-101.
(124) Pelissier E, Nguyen L. [Labile blood product traceability: definition, regulation, evaluation, and
perspectives.]. Transfus Clin Biol 2000 Jun;7 Suppl 1:72s-4s.
(125) Perez P, Ngombet R, Debeir J, Noel L, Sari F. [Transfusion incidents related to bacterial contamination:
review of the literature and hemovigilance data. For the working group Bacterial incidents of French Blood
Agency, scientific advice of Bacthem and the French hemovigilance network]. Transfus Clin Biol 1998
Jun;5(3):203-10.
(126) Perez P, Salmi LR, Follea G, Schmit JL, de BB, Sudre P, et al. Determinants of transfusion-associated
bacterial contamination: results of the French BACTHEM Case-Control Study. Transfusion 2001
Jul;41(7):862-72.
(127) Peyrard T, Pham BN, Le Pennec PY, Rouger P. Transfusion of rare cryopreserved red blood cell units stored
at -80 degrees C: the French experience. Immunohematology 2009;25(1):13-7.
(128) Py JY, Leo-Kodeli S, Fauveau L, Duedari N, Roubinet F. [Hypotension and adverse transfusion reactions:
from the associated clinical signs to the hypotensive transfusion reaction]. Transfus Clin Biol 2009
Mar;16(1):12-20.
(129) Quaranta JF, Canivet N. [What is the use of hemovigilance?]. Transfus Clin Biol 1998 Dec;5(6):415-21.
(130) Quaranta JF, Canivet N, Courbil R, Raucoules-Aime M. [Transfusion safety and haemovigilance
committees]. Transfus Clin Biol 2007 May;14(1):107-11.
(131) Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, et al. Transfusion of platelet
components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus
epidemic in Ile de La Reunion. Transfusion 2009 Jun;49(6):1083-91.
(132) Raynal MJ. [Identity vigilance and implementation of transfusion software in hospitals]. Transfus Clin Biol
2008 Nov;15(5):274-6.
(133) Rebibo D, Morel P, Hauser L, Herve P. [Blood transfusion surveillance: organization and results]. Rev Prat
2001 Jun 30;51(12):1332-6.
(134) Rebibo D, Hauser L, Slimani A, Herve P, Andreu G. The French Haemovigilance System: organization and
results for 2003. Transfus Apher Sci 2004 Oct;31(2):145-53.
(135) Rebibo D, Danic B. [Haemovigilance donors: methods and results]. Transfus Clin Biol 2007 May;14(1):1426.
(136) Reesink HW, Panzer S, Gonzalez CA, Lena N, Muntaabski P, Gimbatti S, et al. Haemovigilance for the
optimal use of blood products in the hospital. Vox Sang 2010 Mar 21.
(137) Reilly M, Szulkin R. Statistical analysis of donation--transfusion data with complex correlation. Stat Med
2007 Dec 30;26(30):5572-85.
(138) Renaudier P, Brunie J, Vial J, Campergue L, Augey L, Arnuti B, et al. [Evaluation of adherence to the
regulations for declaration of notification of transfusion reactions with fever and chills. A study of the
Association Inter-Regionale du Sud-Est d'Hemovigilance (AIRSEH)]. Transfus Clin Biol 2003
Oct;10(5):324-30.
(139) Renaudier P, Rebibo D, Waller C, Schlanger S, Vo Mai MP, Ounnoughene N, et al. [Pulmonary
complications of transfusion (TACO-TRALI)]. Transfus Clin Biol 2009 May;16(2):218-32.
(140) Renom P, Wibaut B, Savage C, Vannier V, Goudemand J. [Diagnostic difficulties of transfusion incidents due
to bacterial contamination: report of two cases]. Transfus Clin Biol 1999 Apr;6(2):124-8.
(141) Robillard P, Chan P, Kleinman S. Hemovigilance for improvement of blood safety. Transfus Apher Sci 2004
Oct;31(2):95-8.
(142) Robillard P, Nawej KI, Jochem K. The Quebec hemovigilance system: description and results from the first
two years. Transfus Apher Sci 2004 Oct;31(2):111-22.
(143) Romeiras MC. [Transfusion safety and hemosurveillance]. Acta Med Port 2000 Jul;13(4):199-202.
(144) Rouger P, Hergon E. [Contribution of hemovigilance to immunologic safety of blood transfusions:
assessment after 3 years]. Transfus Clin Biol 1998 Jun;5(3):219-24.
(145) Rouger P. [From malaria to post-transfusional malaria]. Transfus Clin Biol 1999 Feb;6(1):72-4.
(146) Rouger P, Noizat-Pirenne F, Le Pennec PY. Haemovigilance and transfusion safety in France. Vox Sang
2000;78 Suppl 2:287-9.
(147) Rouger P, Le Pennec PY, Noizat-Pirenne F. [Immunologic risk analysis of blood transfusion: 1991-1998].
Transfus Clin Biol 2000 Feb;7(1):9-14.
(148) Rouger P, Noizat-Pirenne F, Ansart-Pirenne H, Le Pennec PY. [The French reference laboratory for rare
blood groups: activities in 2001]. Transfus Clin Biol 2003 Feb;10(1):41-6.
(149) Rouger P. [Perspectives and organisation of haemovigilance in compliance with the European Directive
2002/98/EC]. Transfus Clin Biol 2004 Jul;11(3):119-22.
(150) Rouger P. [Blood transfusion in the European Union: current status and future challenges]. Bull Acad Natl
Med 2006 Jan;190(1):189-203.
(151) Sachs UJ, Bein G. [Transfusion-related acute lung injury (TRALI)]. Anasthesiol Intensivmed Notfallmed
Schmerzther 2007 Nov;42(11):774-82.
(152) Salmi LR. [Epidemiological support in blood surveillance]. Transfus Clin Biol 1994;1(6):421-4.
(153) Samolyk KA. State-of-the-art blood management in cardiac surgery. Semin Cardiothorac Vasc Anesth 2009
Jun;13(2):118-21.
(154) Schmidt PJ, Leacock AG. Forgotten transfusion history: John Leacock of Barbados. BMJ 2002 Dec
21;325(7378):1485-7.
(155) Siegenthaler MA, Schneider P, Vu DH, Tissot JD. Haemovigilance in a general university hospital: need for a
more comprehensive classification and a codification of transfusion-related events. Vox Sang 2005
Jan;88(1):22-30.
(156) Staccini P, Quaranta JF, Hergon E, Joubert M, Fieschi M. [Computer-based hospital transfusion process: why
and how does one establish a link between continuous quality improvement and clinical information
system?]. Transfus Clin Biol 2000 Apr;7(2):140-52.
(157) Stainsby D. Haemovigilance in the United Kingdom and Europe. Hematol J 2004;5 Suppl 3:S175-S178.
(158) Stainsby D, Williamson L, Jones H, Cohen H. 6 Years of shot reporting--its influence on UK blood safety.
Transfus Apher Sci 2004 Oct;31(2):123-31.
(159) Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, et al. Serious hazards of transfusion: a
decade of hemovigilance in the UK. Transfus Med Rev 2006 Oct;20(4):273-82.
(160) Strengers PF. Is haemovigilance improving transfusion practice?--The european experience. Dev Biol (Basel)
2007;127:215-24.
(161) Sullivan P. Developing an administrative plan for transfusion medicine--a global perspective. Transfusion
2005 Oct;45(4 Suppl):224S-40S.
(162) Tagny CT, Mbanya D, Tapko JB, Lefrere JJ. Blood safety in Sub-Saharan Africa: a multi-factorial problem.
Transfusion 2008 Jun;48(6):1256-61.
(163) Tawfick WA, O'Connor M, Hynes N, Sultan S. Implementation of the Continuous AutoTransfusion System
(C.A.T.S) in open abdominal aortic aneurysm repair: an observational comparative cohort study. Vasc
Endovascular Surg 2008 Feb;42(1):32-9.
(164) Tazi I, Loukhmas L, Benchemsi N. [Haemovigilance: state 1995-2003 Casablanca]. Transfus Clin Biol 2005
Jul;12(3):257-74.
(165) te Boekhorst PA, Beckers EA, Vos MC, Vermeij H, van Rhenen DJ. Clinical significance of bacteriologic
screening in platelet concentrates. Transfusion 2005 Apr;45(4):514-9.
(166) Tinegate HN, Davies T, Elshaw RJ, Jane G, Lyon M, Norfolk DR, et al. When and why is blood
crossmatched? Vox Sang 2010 Feb 25.
(167) Todd A. Haemovigilance--closing the loop. Vox Sang 2002 Aug;83 Suppl 1:13-6.
(168) Tonnetti L, Eder AF, Dy B, Kennedy J, Pisciotto P, Benjamin RJ, et al. Transfusion-transmitted Babesia
microti identified through hemovigilance. Transfusion 2009 Dec;49(12):2557-63.
(169) Trophilme C, Francois A, Pelissier E, Cabaud JJ, Desaint C, Ferrer LF, et al. [Supplying surgery blocs in red
cell concentrates: a collective approach to improve practices]. Transfus Clin Biol 2008 Dec;15(6):390-4.
(170) van Aken WG, van Rood JJ. [Safety of blood transfusions; need for 'hemo-vigilance']. Ned Tijdschr
Geneeskd 1998 Feb 7;142(6):281-4.
(171) van Aken WG. Haemovigilance: a view of a transfusionist. Dev Biol (Basel) 2002;108:9-12.
(172) van Aken WG. [Hemovigilance: a joint responsibility of hospitals and blood banks]. Ned Tijdschr Geneeskd
2003 Aug 2;147(31):1490-2.
(173) van der Poel CL. Hepatitis C virus and blood transfusion: past and present risks. J Hepatol 1999;31 Suppl
1:101-6.
(174) Vlaar AP, Wortel K, Binnekade JM, van Oers MH, Beckers E, Gajic O, et al. The practice of reporting
transfusion-related acute lung injury: a national survey among clinical and preclinical disciplines. Transfusion
2010 Feb;50(2):443-51.
(175) Wagner SJ. Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang 2004
Apr;86(3):157-63.
(176) Waller C, Vicariot M, Gunzberger H. [Analysis of transfusion incident reports filed at 15 blood transfusion
centers and health facilities during 17 months. Groupe Receveurs de laSFTS]. Transfus Clin Biol 1997
Dec;4(6):541-8.
(177) Walther-Wenke G, Schrezenmeier H, Deitenbeck R, Geis G, Burkhart J, Hochsmann B, et al. Screening of
platelet concentrates for bacterial contamination: spectrum of bacteria detected, proportionof transfused units,
and clinical follow-up. Ann Hematol 2009 May 30.
(178) Weiller J, Delbosc A, Greffier A. [Haemovigilance in the health care establishment: its role in pediatric
transfusion]. Transfus Clin Biol 2003 Oct;10(5):353-62.
(179) Weiller J, Delbosc A, Greffier A. [Hemovigilance and pediatrics. Self assessment questions]. Transfus Clin
Biol 2004 Apr;11(2):113.
(180) Wiersum-Osselton JC, Schipperus MR. [Transfusion reactions in patients: haemovigilance reports to the
Dutch National Haemovigilance Office in 2003]. Ned Tijdschr Geneeskd 2005 Nov 19;149(47):2622-7.
(181) Wiersum-Osselton JC, Schipperus MR. Response to the international forum on haemovigilance. Vox Sang
2006 Oct;91(3):278-9.
(182) Wilkinson J, Wilkinson C. Administration of blood transfusions to adults in general hospital settings: a
review of the literature. J Clin Nurs 2001 Mar;10(2):161-70.
(183) Williamson L, Cohen H, Love E, Jones H, Todd A, Soldan K. The Serious Hazards of Transfusion (SHOT)
initiative: the UK approach to haemovigilance. Vox Sang 2000;78 Suppl 2:291-5.
(184) Williamson LM. Systems contributing to the assurance of transfusion safety in the United Kingdom. Vox
Sang 1999;77(2):82-7.
(185) Williamson LM. Using haemovigilance data to set blood safety priorities. Vox Sang 2002 Aug;83 Suppl 1:659.
(186) Williamson LM, Stainsby D, Jones H, Love E, Chapman CE, Navarrete C, et al. The impact of universal
leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusionassociated graft-versus-host disease. Transfusion 2007 Aug;47(8):1455-67.
(187) Win N, Massey E, Lucas G, Sage D, Brown C, Green A, et al. Ninety-six suspected transfusion related acute
lung injury cases: investigation findings and clinical outcome. Hematology 2007 Oct;12(5):461-9.
(188) Zou S, Wu Y, Cable R, Dorsey K, Tang Y, Hapip CA, et al. A prospective study of multiple donor exposure
blood recipients: surveillance value and limitations for hemovigilance. Transfusion 2010 Jan;50(1):128-38.